A5010997820- Prostate Cancer Treatment and Research
- Estrogen and related hormone effects
- Cancer Immunotherapy and Biomarkers
- Advanced Proteomics Techniques and Applications
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Peptidase Inhibition and Analysis
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Steroid Chemistry and Biochemistry
- Autoimmune and Inflammatory Disorders
- Monoclonal and Polyclonal Antibodies Research
- Chemical Synthesis and Analysis
- Mass Spectrometry Techniques and Applications
- Sarcoidosis and Beryllium Toxicity Research
- Gastric Cancer Management and Outcomes
- Hematological disorders and diagnostics
- Ovarian cancer diagnosis and treatment
- Biochemical and Molecular Research
- Protein Kinase Regulation and GTPase Signaling
- Cancer Genomics and Diagnostics
- Gallbladder and Bile Duct Disorders
- Ubiquitin and proteasome pathways
- Immunodeficiency and Autoimmune Disorders
- Neuroblastoma Research and Treatments
- SARS-CoV-2 and COVID-19 Research
Icahn School of Medicine at Mount Sinai
2024
NYU Langone Health
2022-2024
NYU Langone’s Laura and Isaac Perlmutter Cancer Center
2023
New York University
2023
Hacettepe University Hospital
2021
Ankara University
2021
Hacettepe University
2021
Salk Institute for Biological Studies
2019
Abstract Sarcoidosis is an idiopathic inflammatory disorder that commonly treated with glucocorticoids. An imprecise understanding of the immunologic changes underlying sarcoidosis has limited therapeutic progress. Here in this open-label trial (NCT03910543), 10 patients cutaneous are tofacitinib, a Janus kinase inhibitor. The primary outcome change activity and morphology instrument (CSAMI) score after 6 months treatment. Secondary outcomes included internal organ involvement, molecular...
Advanced hepatocellular carcinoma (HCC) generally has a dismal prognosis. Bone metastases from HCC are infrequent, with poorer However, the survival influencing factors not yet well understood.The aim of present study was to assess clinical features and tumor characteristics patients bone metastasis.A cohort 170,576 adult studied using National Cancer Database (NCDB) spanning 2010 2019, within this group, 5285 (3.1%) were diagnosed metastasis. We performed Kaplan-Meier method calculate...
Abstract Prostate cancers adapt to androgen receptor (AR) pathway inhibitors and progress castration resistance due ongoing AR expression function. To counter this, we developed a new approach modulate the inhibit castration-resistant prostate cancer (CRPC) using multivalent peptoid conjugates (MPC) that contain multiple copies of AR-targeting ligand ethisterone attached peptidomimetic scaffold. Here, investigated antitumor effects compound MPC309, trivalent display conjugated oligomer...
Abstract Sarcoidosis is an idiopathic inflammatory disorder that commonly treated with glucocorticoids and there are no approved steroid-sparing medications. There emerging evidence Janus kinase (JAK) inhibitors, which inhibit JAK-dependent cytokine activity, may hold promise in sarcoidosis. In this open-label trial, 10 patients recalcitrant sarcoidosis cutaneous involvement were tofacitinib 5 mg twice daily. was washout period permitted to continue, taper, or discontinue other treatments....
In parallel to the increased vaccination rates of cancer patients, real-world data will show long-term safety mRNA-based COVID-19 vaccines in patients treated with ICIs."
Pancreaticductal adenocarcinoma (PDAC) is a cancer of the exocrine pancreas with an aggressive prognosis (a 5-year survival rate 6 months), resulting in more than 250,000 deaths per year. PDAC fourth most common cause cancer-related mortality worldwide. resistant to chemotherapy other types due dense fibrosis around it. Moreover, only 15% patients who have tumors can surgical resection. Consequently, success and surgery treatments limited, motivating researchers turn immunotherapy...
<p>Chemical structures and IC50 of the multivalent ethisterone-peptoid conjugate</p>
<p>Figure legends for the supplemental data</p>
<p>PK of MPC309 and effects on immune cells</p>
<p>Figure legends for the supplemental data</p>
<p>PK of MPC309 and effects on immune cells</p>
<p>Effects of MPC309 versus ethisterone on gene expression in LNCaP-abl cells</p>
<p>Comparison of MPC309 antiproliferative activity in DU145, PC3, LNCaP and 22Rv1 effects on AR-dependent gene expression</p>
<p>Model for MPC309 effect on AR-dependent gene expression</p>
<p>Effects of MPC309 versus ethisterone on gene expression in LNCaP-abl cells</p>
<p>Comparison of MPC309 antiproliferative activity in DU145, PC3, LNCaP and 22Rv1 effects on AR-dependent gene expression</p>
<p>Model for MPC309 effect on AR-dependent gene expression</p>